These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 23374557)
1. Clinical value of whole-body F-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with carcinoma of unknown primary. Wang G; Wu Y; Zhang W; Li J; Wu P; Xie C J Med Imaging Radiat Oncol; 2013 Feb; 57(1):65-71. PubMed ID: 23374557 [TBL] [Abstract][Full Text] [Related]
2. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site. Pelosi E; Pennone M; Deandreis D; Douroukas A; Mancini M; Bisi G Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):15-22. PubMed ID: 16557200 [TBL] [Abstract][Full Text] [Related]
3. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary. Han A; Xue J; Hu M; Zheng J; Wang X Cancer Epidemiol; 2012 Oct; 36(5):470-5. PubMed ID: 22504050 [TBL] [Abstract][Full Text] [Related]
4. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors. Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY Oral Oncol; 2009 Mar; 45(3):218-24. PubMed ID: 18804404 [TBL] [Abstract][Full Text] [Related]
5. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors]. Wu ZJ; Zhang YX; Wei H; Jia Q Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544 [TBL] [Abstract][Full Text] [Related]
6. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736 [TBL] [Abstract][Full Text] [Related]
7. Is there an added clinical value of "true"whole body(18)F-FDG PET/CT imaging in patients with malignant melanoma? Tan JC; Chatterton BE Hell J Nucl Med; 2012; 15(3):202-5. PubMed ID: 23106051 [TBL] [Abstract][Full Text] [Related]
8. Detection of occult primary tumors in patients with cervical metastases of unknown primary tumors: comparison of (18)F FDG PET/CT with contrast-enhanced CT or CT/MR imaging-prospective study. Lee JR; Kim JS; Roh JL; Lee JH; Baek JH; Cho KJ; Choi SH; Nam SY; Kim SY Radiology; 2015 Mar; 274(3):764-71. PubMed ID: 25405771 [TBL] [Abstract][Full Text] [Related]
9. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle. Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129 [TBL] [Abstract][Full Text] [Related]
10. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer. Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010 [TBL] [Abstract][Full Text] [Related]
11. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study. Klenk C; Gawande R; Uslu L; Khurana A; Qiu D; Quon A; Donig J; Rosenberg J; Luna-Fineman S; Moseley M; Daldrup-Link HE Lancet Oncol; 2014 Mar; 15(3):275-85. PubMed ID: 24559803 [TBL] [Abstract][Full Text] [Related]
12. Supplemental value of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) technique to whole-body magnetic resonance imaging in detection of bone metastases from thyroid cancer. Sakurai Y; Kawai H; Iwano S; Ito S; Ogawa H; Naganawa S J Med Imaging Radiat Oncol; 2013 Jun; 57(3):297-305. PubMed ID: 23721138 [TBL] [Abstract][Full Text] [Related]
13. In-line (18)F-fluorodeoxyglucose positron emission tomography with computed tomography (PET/CT) in patients with carcinoma of the sinus/nasal area and orbit. Wild D; Eyrich GK; Ciernik IF; Stoeckli SJ; Schuknecht B; Goerres GW J Craniomaxillofac Surg; 2006 Jan; 34(1):9-16. PubMed ID: 16343913 [TBL] [Abstract][Full Text] [Related]
14. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin. Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438 [TBL] [Abstract][Full Text] [Related]
15. Delayed response assessment with FDG-PET-CT following (chemo) radiotherapy for locally advanced head and neck squamous cell carcinoma. Prestwich RJ; Subesinghe M; Gilbert A; Chowdhury FU; Sen M; Scarsbrook AF Clin Radiol; 2012 Oct; 67(10):966-75. PubMed ID: 22595082 [TBL] [Abstract][Full Text] [Related]
16. F-18 FDG PET/CT in the diagnosis of fever of unknown origin. Balink H; Collins J; Bruyn GA; Gemmel F Clin Nucl Med; 2009 Dec; 34(12):862-8. PubMed ID: 20139818 [TBL] [Abstract][Full Text] [Related]
17. Fever of unknown origin: the role of 18F-FDG PET/CT. Keidar Z; Gurman-Balbir A; Gaitini D; Israel O J Nucl Med; 2008 Dec; 49(12):1980-5. PubMed ID: 18997040 [TBL] [Abstract][Full Text] [Related]
18. Role of fluorodeoxyglucose-PET versus fluorodeoxyglucose-PET/computed tomography in detection of unknown primary tumor: a meta-analysis of the literature. Dong MJ; Zhao K; Lin XT; Zhao J; Ruan LX; Liu ZF Nucl Med Commun; 2008 Sep; 29(9):791-802. PubMed ID: 18677207 [TBL] [Abstract][Full Text] [Related]
20. Thyroid incidentalomas on FDG PET/CT in patients with non-thyroid cancer - a large retrospective monocentric study. Kim H; Kim SJ; Kim IJ; Kim K Onkologie; 2013; 36(5):260-4. PubMed ID: 23689220 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]